山东威海税务以切实举措让合规经营成为企业“必选题”

Core Viewpoint - Shandong Weigao Orthopedic Materials Co., Ltd. has established itself as a leading player in the orthopedic medical device industry in China, focusing on tax compliance and innovation to enhance its competitive edge [1][2]. Group 1: Company Overview - Weigao Orthopedic has been recognized as an A-level taxpayer multiple times and has achieved a "nine consecutive A" tax credit status as of this year [1]. - Since its establishment in 2005, the company has developed a comprehensive product line covering over 20,000 different specifications in orthopedic implants, making it the market leader in China [1]. - The company holds 377 domestic patents, indicating a strong focus on research and development [1]. Group 2: Innovation and R&D - Weigao Orthopedic invests over 70 million annually in R&D, with a consistent increase in funding [1]. - The company is facing challenges due to the monopoly of key technologies abroad, which poses risks to its operations [1]. - In 2024, the company is expected to benefit from over 58 million in R&D expense deductions, highlighting the financial advantages of tax policies [2]. Group 3: Compliance and Management - The company views compliance management as a strategic choice rather than a reactive measure, integrating it into its corporate culture [2]. - A comprehensive tax internal control system has been established, detailing processes from contract review to tax accounting and reporting [2]. - The local tax authority provides support through risk scanning and specialized tax service teams, aiding the company in establishing standardized tax operation manuals [3]. Group 4: Future Outlook - The company aims to enhance its tax compliance management system to strengthen risk prevention and align itself with international standards [3].